Adenosine and anergy

References

• Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International union of pharmacology XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53(4)527–552
   PubMed Web of Science ®Google Scholar
• Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414(6866)916–920
   PubMed Web of Science ®Google Scholar
• Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+T cells. J Immunol 2005; 174(2)1073–1080
   PubMedGoogle Scholar
• Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, Fowler DH. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005; 105(12)4707–4714
   PubMed Web of Science ®Google Scholar
• Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. Cutting edge: Physiologic attenuation of proinflammatory transcription by the G(s) protein-coupled A2A adenosine receptor in vivo. J Immunol 2004; 173(1)21–24
   PubMedGoogle Scholar
• Powell JD. The induction and maintenance of T cell anergy. Clin Immunol 2006; 120(3)239–246
   PubMedGoogle Scholar
• Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165(2)302–319
   PubMed Web of Science ®Google Scholar
• Lerner CG, Horton MR, Schwartz RH, Powell JD. Distinct requirements for C–C chemokine and IL-2 production by naive, previously activated, and anergic T cells. J Immunol 2000; 164(8)3996–4002
   PubMedGoogle Scholar
• Chen L, Rao A, Harrison SC. Signal integration by transcription-factor assemblies: Interactions of NF-AT1 and AP-1 on the IL-2 promoter. Cold Spring Harb Symp Quant Biol 1999; 64: 527–531
   PubMedGoogle Scholar
• Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109(6)719–731
   PubMedGoogle Scholar
• Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144(1)16–22
   PubMed Web of Science ®Google Scholar
• Kowalski J, Drake C, Schwartz RH, Powell J. Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypes. Bioinformatics 2004; 20(3)364–373
   PubMedGoogle Scholar
• Safford M, Collins S, Lutz MA, Allen A, Huang CT, Kowalski J, Blackford A, Horton MR, Drake C, Schwartz RH, et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 2005; 6(5)472–480
   PubMedGoogle Scholar
• Anderson PO, Manzo BA, Sundstedt A, Minaee S, Symonds A, Khalid S, Rodriguez-Cabezas ME, Nicolson K, Li S, Wraith DC, et al. Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance. Eur J Immunol 2006; 36(6)1374–1385
   PubMed Web of Science ®Google Scholar
• Harris JE, Bishop KD, Phillips NE, Mordes JP, Greiner DL, Rossini AA, Czech MP. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+T cells. J Immunol 2004; 173(12)7331–7338
   PubMedGoogle Scholar
• Heissmeyer V, Macian F, Im SH, Varma R, Feske S, Venuprasad K, Gu H, Liu YC, Dustin ML, Rao A. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signalling proteins. Nat Immunol 2004; 5(3)255–265
   PubMedGoogle Scholar
• Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, Seroogy C, Skrenta H, Hollenhorst M, Fathman CG, Soares L. GRAIL: An E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+T cells. Immunity 2003; 18(4)535–547
   PubMedGoogle Scholar
• Jeon MS, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, Yang C, Arya S, Bachmaier K, Su L. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004; 21(2)167–177
   PubMed Web of Science ®Google Scholar
• Seroogy CM, Soares L, Ranheim EA, Su L, Holness C, Bloom D, Fathman CG. The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 2004; 173(1)79–85
   PubMedGoogle Scholar
• Mueller DL. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 2004; 5(9)883–890
   PubMedGoogle Scholar
• Li W, Whaley CD, Mondino A, Mueller DL. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+T cells. Science 1996; 271(5253)1272–1276
   PubMedGoogle Scholar
• Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+T cells. Science 1996; 271(5253)1276–1278
   PubMedGoogle Scholar
• Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science 1997; 278(5335)124–128
   PubMedGoogle Scholar
• Li L, Greenwald RJ, Lafuente EM, Tzachanis D, Berezovskaya A, Freeman GJ, Sharpe AH, Boussiotis VA. Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol 2005; 175(5)3133–3139
   PubMedGoogle Scholar
• Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006; 7(11)1166–1173
   PubMed Web of Science ®Google Scholar
• Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, Zhong XP. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 2006; 7(11)1174–1181
   PubMed Web of Science ®Google Scholar
• Powell JD, Lerner CG, Ewoldt GR, Schwartz RH. The − 180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol 1999; 163(12)6631–6639
   PubMedGoogle Scholar
• Telander DG, Malvey EN, Mueller DL. Evidence for repression of IL-2 gene activation in anergic T cells. J Immunol 1999; 162(3)1460–1465
   PubMedGoogle Scholar
• Tenbrock K, Juang YT, Tolnay M, Tsokos GC. The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J Immunol 2003; 170(6)2971–2976
   PubMedGoogle Scholar
• Solomou EE, Juang YT, Tsokos GC. Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the − 180 site of the IL-2 promoter in normal human T lymphocytes. J Immunol 2001; 166(9)5665–5674
   PubMedGoogle Scholar
• Bandyopadhyay S, Dure M, Paroder M, Soto-Nieves N, Puga I, Macian F. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood 2006
   Google Scholar
• Thomas RM, Gao L, Wells AD. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol 2005; 174(8)4639–4646
   PubMedGoogle Scholar
• Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6(4)411–417
   PubMed Web of Science ®Google Scholar
• Adler AJ, Huang CT, Yochum GS, Marsh DW, Pardoll DM. In vivo CD4+T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol 2000; 164(2)649–655
   PubMedGoogle Scholar
• Rocha B, Tanchot C, Von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 1993; 177(5)1517–1521
   PubMed Web of Science ®Google Scholar
• Rocha B, Grandien A, Freitas AA. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J Exp Med 1995; 181(3)993–1003
   PubMedGoogle Scholar
• Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95(3)1178–1183
   PubMedGoogle Scholar
• Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14(2)145–155
   PubMed Web of Science ®Google Scholar
• Pape KA, Kearney ER, Khoruts A, Mondino A, Merica R, Chen ZM, Ingulli E, White J, Johnson JG, Jenkins MK. Use of adoptive transfer of T cell-antigen-receptor-transgenic T cell for the study of T cell activation in vivo. Immunol Rev 1997; 156: 67–78
   PubMedGoogle Scholar
• Huang CT, Huso DL, Lu Z, Wang T, Zhou G, Kennedy EP, Drake CG, Morgan DJ, Sherman LA, Higgins AD, et al. CD4+T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol 2003; 170(8)3945–3953
   PubMedGoogle Scholar
• Andris F, Denanglaire S, de Mattia F, Urbain J, Leo O. Naive T cells are resistant to anergy induction by anti-CD3 antibodies. J Immunol 2004; 173(5)3201–3208
   PubMed Web of Science ®Google Scholar
• Hayashi RJ, Loh DY, Kanagawa O, Wang F. Differences between responses of naive and activated T cells to anergy induction [in process citation]. J Immunol 1998; 160(1)33–38
   PubMedGoogle Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21: 305–334
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA, Jr. How does the immune system distinguish self from nonself?. Semin Immunol 2000; 12(3)185–188, discussion 257–344
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system?. Semin Immunol 1996; 8(5)271–280
   PubMedGoogle Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425(6957)516–521
   PubMed Web of Science ®Google Scholar
• Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192(4)565–570
   PubMed Web of Science ®Google Scholar
• Powell JD, Horton MR. Threat matrix: Low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res 2005; 31(3)207–218
   PubMed Web of Science ®Google Scholar
• Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, Powell JD. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007; 178(4)2163–2170
   PubMedGoogle Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18(16)1926–1945
   PubMed Web of Science ®Google Scholar
• Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162(5)2775–2784
   PubMed Web of Science ®Google Scholar
• Vanasek TL, Khoruts A, Zell T, Mueller DL. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: Enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol 2001; 167(10)5636–5644
   PubMed Web of Science ®Google Scholar
• Allen A, Zheng Y, Gardner L, Safford M, Horton MR, Powell JD. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 2004; 172(8)4797–4803
   PubMedGoogle Scholar
• Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000; 362(4–5)299–309
   PubMedGoogle Scholar
• Williams TC, Jarvis SM. Multiple sodium-dependent nucleoside transport systems in bovine renal brush-border membrane vesicles. Biochem J 1991; 274(Pt 1)27–33
   PubMedGoogle Scholar
• Berne RM, Rubio R. Adenine nucleotide metabolism in the heart. Circ Res 1974; 35(Suppl 3)109–120
   PubMedGoogle Scholar
• Latini S, Bordoni F, Pedata F, Corradetti R. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 1999; 127(3)729–739
   PubMedGoogle Scholar
• Latini S, Bordoni F, Corradetti R, Pepeu G, Pedata F. Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 1999; 128(5)1035–1044
   PubMedGoogle Scholar
• Lloyd HG, Fredholm BB. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int 1995; 26(4)387–395
   PubMedGoogle Scholar
• Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997; 57(13)2602–2605
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158(4)1160–1177
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76(1)5–13
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78(3)760–770
   PubMedGoogle Scholar
• Newby AC, Holmquist CA, Illingworth J, Pearson JD. The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J 1983; 214(2)317–323
   PubMedGoogle Scholar
• Leonard EJ, Shenai A, Skeel A. Dynamics of chemotactic peptide-induced superoxide generation by human monocytes. Inflammation 1987; 11(2)229–240
   PubMedGoogle Scholar
• Salmon JE, Brogle N, Brownlie C, Edberg JC, Kimberly RP, Chen BX, Erlanger BF. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J Immunol 1993; 151(5)2775–2785
   PubMedGoogle Scholar
• Lappin D, Whaley K. Adenosine A2 receptors on human monocytes modulate C2 production. Clin Exp Immunol 1984; 57(2)454–460
   PubMedGoogle Scholar
• Parmely MJ, Zhou WW, Edwards CK, 3rd, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993; 151(1)389–396
   PubMedGoogle Scholar
• Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997; 280(1)301–309
   PubMedGoogle Scholar
• Ross SD, Tribble CG, Linden J, Gangemi JJ, Lanpher BC, Wang AY, Kron IL. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant 1999; 18(10)994–1002
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Cronstein BN. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003; 48(1)240–247
   PubMedGoogle Scholar
• Okusa MD. A(2A) adenosine receptor: A novel therapeutic target in renal disease. Am J Physiol Renal Physiol 2002; 282(1)F10–F18
   Google Scholar
• Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005; 129(1)26–33
   PubMedGoogle Scholar
• Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203(12)2639–2648
   PubMed Web of Science ®Google Scholar
• Filippini A, Taffs RE, Sitkovsky MV. Extracellular ATP in T-lymphocyte activation: Possible role in effector functions. Proc Natl Acad Sci USA 1990; 87(21)8267–8271
   PubMedGoogle Scholar
• Apasov SG, Koshiba M, Chused TM, Sitkovsky MV. Effects of extracellular ATP and adenosine on different thymocyte subsets: Possible role of ATP-gated channels and G protein-coupled purinergic receptor. J Immunol 1997; 158(11)5095–5105
   PubMedGoogle Scholar
• Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T cell activation and expansion. Blood 1997; 90(4)1600–1610
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors*. Annu Rev Immunol 2004; 22: 657–682
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Immunology: Dangerous liaisons. Nature 2003; 425(6957)460–461
   PubMedGoogle Scholar